216 related articles for article (PubMed ID: 34178875)
1. Targeting TMAO and its metabolic pathway for cardiovascular diseases treatment.
Hoseini-Tavassol Z; Hasani-Ranjbar S
J Diabetes Metab Disord; 2021 Jun; 20(1):1095-1097. PubMed ID: 34178875
[TBL] [Abstract][Full Text] [Related]
2. The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases.
Zhen J; Zhou Z; He M; Han HX; Lv EH; Wen PB; Liu X; Wang YT; Cai XC; Tian JQ; Zhang MY; Xiao L; Kang XX
Front Endocrinol (Lausanne); 2023; 14():1085041. PubMed ID: 36824355
[TBL] [Abstract][Full Text] [Related]
3. Gut Microbiota and Ischemic Stroke: The Role of Trimethylamine N-Oxide.
Nam HS
J Stroke; 2019 May; 21(2):151-159. PubMed ID: 31161760
[TBL] [Abstract][Full Text] [Related]
4. Gut Microbiota-Dependent Marker TMAO in Promoting Cardiovascular Disease: Inflammation Mechanism, Clinical Prognostic, and Potential as a Therapeutic Target.
Yang S; Li X; Yang F; Zhao R; Pan X; Liang J; Tian L; Li X; Liu L; Xing Y; Wu M
Front Pharmacol; 2019; 10():1360. PubMed ID: 31803054
[TBL] [Abstract][Full Text] [Related]
5. Trimethylamine N-Oxide as a Potential Risk Factor for Non-communicable Diseases: A Systematic Review.
Hoseini-Tavassol Z; Ejtahed HS; Larijani B; Hasani-Ranjbar S
Endocr Metab Immune Disord Drug Targets; 2023; 23(5):617-632. PubMed ID: 36330632
[TBL] [Abstract][Full Text] [Related]
6. The Gut Microbial-Derived Metabolite Trimethylamine N-Oxide and Atrial Fibrillation: Relationships, Mechanisms, and Therapeutic Strategies.
Huang R; Yan L; Lei Y
Clin Interv Aging; 2021; 16():1975-1986. PubMed ID: 34876810
[TBL] [Abstract][Full Text] [Related]
7. Impact of trimethylamine N-oxide (TMAO) metaorganismal pathway on cardiovascular disease.
Zhao Y; Wang Z
J Lab Precis Med; 2020 Apr; 5():. PubMed ID: 32587943
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular Health and The Intestinal Microbial Ecosystem: The Impact of Cardiovascular Therapies on The Gut Microbiota.
Alhajri N; Khursheed R; Ali MT; Abu Izneid T; Al-Kabbani O; Al-Haidar MB; Al-Hemeiri F; Alhashmi M; Pottoo FH
Microorganisms; 2021 Sep; 9(10):. PubMed ID: 34683334
[TBL] [Abstract][Full Text] [Related]
9. Trimethylamine N-Oxide, a Gut Microbiota-Derived Metabolite, Is Associated with Cardiovascular Risk in Psoriasis: A Cross-Sectional Pilot Study.
Sikora M; Kiss N; Stec A; Giebultowicz J; Samborowska E; Jazwiec R; Dadlez M; Olszewska M; Rudnicka L
Dermatol Ther (Heidelb); 2021 Aug; 11(4):1277-1289. PubMed ID: 33983475
[TBL] [Abstract][Full Text] [Related]
10. Gut macrobiotic and its metabolic pathways modulate cardiovascular disease.
Zhu J; Lyu J; Zhao R; Liu G; Wang S
Front Microbiol; 2023; 14():1272479. PubMed ID: 37822750
[TBL] [Abstract][Full Text] [Related]
11. Gut microbiota-derived trimethylamine-N-oxide: A bridge between dietary fatty acid and cardiovascular disease?
He M; Tan CP; Xu YJ; Liu Y
Food Res Int; 2020 Dec; 138(Pt B):109812. PubMed ID: 33288187
[TBL] [Abstract][Full Text] [Related]
12. A Multi-omic Association Study of Trimethylamine N-Oxide.
Manor O; Zubair N; Conomos MP; Xu X; Rohwer JE; Krafft CE; Lovejoy JC; Magis AT
Cell Rep; 2018 Jul; 24(4):935-946. PubMed ID: 30044989
[TBL] [Abstract][Full Text] [Related]
13. [Gut microbiota and its metabolite trimethylamine-N-oxide (TMAO): a novel regulator in coronary artery disease].
Li Y; Cui M; Sun J; Wei Q; Liu M; Zhang J; Qi H; Zhao L; Fang H; Chen Z; Lü S
Sheng Wu Gong Cheng Xue Bao; 2021 Nov; 37(11):3745-3756. PubMed ID: 34841781
[TBL] [Abstract][Full Text] [Related]
14. Identification of TMAO-producer phenotype and host-diet-gut dysbiosis by carnitine challenge test in human and germ-free mice.
Wu WK; Chen CC; Liu PY; Panyod S; Liao BY; Chen PC; Kao HL; Kuo HC; Kuo CH; Chiu THT; Chen RA; Chuang HL; Huang YT; Zou HB; Hsu CC; Chang TY; Lin CL; Ho CT; Yu HT; Sheen LY; Wu MS
Gut; 2019 Aug; 68(8):1439-1449. PubMed ID: 30377191
[TBL] [Abstract][Full Text] [Related]
15. Exploring the Microbiome in Heart Failure.
Kitai T; Kirsop J; Tang WH
Curr Heart Fail Rep; 2016 Apr; 13(2):103-9. PubMed ID: 26886380
[TBL] [Abstract][Full Text] [Related]
16. Drug Discovery and Development of Novel Therapeutics for Inhibiting TMAO in Models of Atherosclerosis and Diabetes.
Steinke I; Ghanei N; Govindarajulu M; Yoo S; Zhong J; Amin RH
Front Physiol; 2020; 11():567899. PubMed ID: 33192565
[TBL] [Abstract][Full Text] [Related]
17. The Role of Gut Microbiota and Associated Compounds in Cardiovascular Health and its Therapeutic Implications.
Liu L; Kaur GI; Kumar A; Kanwal A; Singh SP
Cardiovasc Hematol Agents Med Chem; 2024 Jan; ():. PubMed ID: 38275032
[TBL] [Abstract][Full Text] [Related]
18. Cross-Talk between Gut Microbiota and Heart via the Routes of Metabolite and Immunity.
Bu J; Wang Z
Gastroenterol Res Pract; 2018; 2018():6458094. PubMed ID: 29967639
[TBL] [Abstract][Full Text] [Related]
19. Contribution of Trimethylamine N-Oxide (TMAO) to Chronic Inflammatory and Degenerative Diseases.
Constantino-Jonapa LA; Espinoza-Palacios Y; Escalona-Montaño AR; Hernández-Ruiz P; Amezcua-Guerra LM; Amedei A; Aguirre-García MM
Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36830968
[TBL] [Abstract][Full Text] [Related]
20. Trimethylamine N-oxide: A harmful, protective or diagnostic marker in lifestyle diseases?
Nowiński A; Ufnal M
Nutrition; 2018 Feb; 46():7-12. PubMed ID: 29290360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
